Section 2. Colombian consensus for prophylaxis, treatment and prevention of invasive aspergillosis in adult and pediatric patients*;

Autores organización

• Julio Cesar Gomez Rincon

  Autor

• 

  Christian Jose Pallares Gutierrez

  Autor

Autores

• Oñate J.M.
• Rivas-Pinedo P.
• Saavedra-Trujillo C.H.
• Camacho-Moreno G.
• Enciso-Olivera L.
• Cuervo-Maldonado S.I.
• Patiño-Escobar B.
• Osorio-Lombana J.P.
• Berrio I.
• Álvarez-Moreno C.A.
• Restrepo-Gualteros S.
• Castañeda-Luquerna X.
• Guevara F.
• Marín-Uribe J.I.
• Patiño-Niño J.
• García-Goez J.F.
• Celis A.M.
• Montufar F.
• López-Medina E.
• Fernández-Chico D.
• Fernández-Suarez H.

Grupos de investigación

• Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria RAEH

  

  Investigador

  Maria Virginia Villegas Botero

Resumen

Resumen no disponible

Keywords

• antifungal agent; colony stimulating factor; immunosuppressive agent; adult; AIDS patient; algorithm; antibiotic prophylaxis; antifungal therapy; antimicrobial stewardship; Aspergillus; biological therapy; cancer chemotherapy; child; chronic disease; clinical protocol; Colombia; comorbidity; consensus; coronavirus disease 2019; critically ill patient; diagnostic procedure; disease risk assessment; drug choice; drug efficacy; drug targeting; environmental exposure; follow up; genetic polymorphism; graft recipient; graft versus host reaction; granulocyte transfusion; heart transplantation; hematologic malignancy; hematopoietic stem cell transplantation; high risk patient; high risk population; human; Human immunodeficiency virus infected patient; immune deficiency; immunocompromised patient; immunomodulation; immunosuppressive treatment; infection prevention; infection risk; intensive care unit; invasive aspergillosis; invasive pulmonary aspergillosis; lung aspergillosis; lung transplant